PAHC Quote, Financials, Valuation and Earnings

AtriCure, Inc. has a net margin of 7.34% compared to Phibro Animal Health Corp.'s net margin of 1.25%. Phibro Animal Health Corp.'s return on equity of 31.92% beat AtriCure, Inc.'s return on equity of -2.44%.

Phibro Animal Health Corp. has a consensus price target of $48.50, signalling downside risk potential of -7.21%. On the other hand AtriCure, Inc. has an analysts' consensus of $49.38 which suggests that it could grow by 56.95%. Given that AtriCure, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe AtriCure, Inc. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.738, which suggesting that the stock is 26.235% less volatile than S&P 500. In comparison AtriCure, Inc. has a beta of 1.423, suggesting its more volatile than the S&P 500 by 42.295%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 0.92%. AtriCure, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. AtriCure, Inc. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $373.9M, which are larger than AtriCure, Inc. quarterly revenues of $140.5M. Phibro Animal Health Corp.'s net income of $27.5M is higher than AtriCure, Inc.'s net income of $1.8M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 23.17x while AtriCure, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.46x versus 2.81x for AtriCure, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 7.34% compared to Phibro Animal Health Corp.'s net margin of 12.68%. Phibro Animal Health Corp.'s return on equity of 31.92% beat Boston Scientific Corp.'s return on equity of 12.55%.

Phibro Animal Health Corp. has a consensus price target of $48.50, signalling downside risk potential of -7.21%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 41.84%. Given that Boston Scientific Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Boston Scientific Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.738, which suggesting that the stock is 26.235% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 0.92%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $373.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Phibro Animal Health Corp.'s net income of $27.5M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 23.17x while Boston Scientific Corp.'s PE ratio is 38.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.46x versus 5.50x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 7.34% compared to Phibro Animal Health Corp.'s net margin of 12.96%. Phibro Animal Health Corp.'s return on equity of 31.92% beat Insulet Corp.'s return on equity of 17.89%.

Phibro Animal Health Corp. has a consensus price target of $48.50, signalling downside risk potential of -7.21%. On the other hand Insulet Corp. has an analysts' consensus of $354.40 which suggests that it could grow by 46.54%. Given that Insulet Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Insulet Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.738, which suggesting that the stock is 26.235% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.204%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 0.92%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $373.9M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. Phibro Animal Health Corp.'s net income of $27.5M is lower than Insulet Corp.'s net income of $101.6M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 23.17x while Insulet Corp.'s PE ratio is 69.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.46x versus 6.39x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 7.34% compared to Phibro Animal Health Corp.'s net margin of 27.59%. Phibro Animal Health Corp.'s return on equity of 31.92% beat ResMed, Inc.'s return on equity of 25.44%.

Phibro Animal Health Corp. has a consensus price target of $48.50, signalling downside risk potential of -7.21%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 15.17%. Given that ResMed, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe ResMed, Inc. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.738, which suggesting that the stock is 26.235% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.877, suggesting its less volatile than the S&P 500 by 12.278%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 0.92%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $373.9M, which are smaller than ResMed, Inc. quarterly revenues of $1.4B. Phibro Animal Health Corp.'s net income of $27.5M is lower than ResMed, Inc.'s net income of $392.6M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 23.17x while ResMed, Inc.'s PE ratio is 25.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.46x versus 7.03x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.